Approved Products and Development Pipeline
* Click here for JUXTAPID® (lomitapide) full prescribing information, including boxed warning for the risk of hepatotoxicity.
** Click here for MYALEPT® (metreleptin) full prescribing information, including boxed warning for the risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma.
Our Pipeline: Status of Selected Key Development Programs as of October 2018
Represents current phase1 of development; does not correspond to initiation or completion of a particular phase1.
*** Additional development is subject to, among other things, the successful completion of the company’s ongoing capital structure review and our ability to design and fund the R+D efforts necessary to pursue FDA and other regulatory approvals.
1 Data on file